Compounded GLP-1 write-down drives Hims & Hers Health stock lower by 14.10%

Traders Union
All News
Financial News
Hims & Hers Health slides 14.10% today

Highlights

Hims & Hers Health reported a net loss of $92.1 million in Q1 2026, missing analyst expectations due to $33 million in restructuring charges tied to compounded GLP-1 inventory write-downs.
Revenue increased 4% to $608 million, with international sales reaching $78 million on acquisition-driven growth, but these gains failed to offset operational losses.
Shares trade under key moving averages amid persistent downside pressure; technicals signal low probability of near-term rally, with consolidation expected between $23.00 and $27.50.

Operational charges and GLP-1 write-down drive quarterly net loss

On May 12, 2026, Hims & Hers Health reported first-quarter results that missed analyst expectations, posting a net loss of $92.1 million compared to net income of $49.5 million a year earlier. The loss was primarily driven by $33 million in restructuring charges related to the write-down of compounded GLP-1 inventory following the company's shift in focus to branded weight-loss drugs, such as those distributed through its partnership with Novo Nordisk. While quarterly revenue grew 4% to $608 million and international revenue rose to $78 million on the back of acquisitions, these gains were insufficient to offset the headline loss and operational charges.

Resistance at $25.41 as volatility spikes and indicators oversold

The MA-20 is at $27.77, the MA-50 at $23.66, and the MA-200 at $36.41, with HIMS currently positioned between the MA-50 and MA-20. The Ichimoku Kijun sits at $25.41, indicating immediate resistance overhead. The session opened at $25.25, significantly below the prior close, creating a wide intraday range of $24.58–$26.75 and highlighting elevated volatility. On the indicator front, RSI stands at 47.39, with Stoch RSI and CCI both entering oversold territory. MACD on D1 reveals continued upward potential, while ADX indicates moderate trend strength. BBP remains negative and in oversold mode, signaling that sellers retain dominance over intraday momentum.

Limited upside expected as consolidation persists within volatility band

Over the next five sessions, the anticipated volatility band is $23.00 to $27.50. The probability of a sustained upside move remains low, with less than a 20% chance of a material rally. Baseline expectations are for HIMS to consolidate within this range unless momentum shifts. A decisive break above $25.41 could prompt a retest of higher resistances, whereas persistence of selling pressure would increase risk of a move below $23.00.

Viktoras Karapetjanc, expert at Traders Union, sees Hims & Hers Health pressured by a sharp earnings miss and negative sentiment after the Q1 2026 net loss. He notes that fundamental shifts, like the restructuring charges and business transition, are weighing on confidence despite stronger international revenue and improved guidance. The analyst believes price action may stay volatile but expects the stock to consolidate unless buyers reclaim resistance. "Momentum is fragile here, but if HIMS can hold above the $25.41 level and investors refocus on the long-term outlook, the risk-to-reward will start to improve."

Earlier, analysts noted that Hims & Hers Health was likely to consolidate as mixed technical signals and ongoing business developments suggested limited momentum for a decisive move. The latest pullback below immediate resistance following disappointing earnings further reinforces this sideways-to-cautious outlook, making the $23.00 level critical for downside risk management in the near term.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.